Therefore, it could be inferred that TREM-2 might amplify the inflammatory response in human acquired cholesteatoma and then increase the proinflammatory cytokines levels (IL-1β, TNF-α, and IL-6) while promoting MMP secretion. The gene discussed is IL6; the disease is cholesteatoma.